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pathophysiologyThyroid-associated orbitopathy (TAO) or thyroid eye disease
is the most common cause of unilateral or bilateral proptosis
in adults. The disease is more prevalent in female patients than
male counterparts with annual incidence being 16/100,000 in
women and 3/100,000 in men (Stiebel-Kalish et al., 2009; Yang
et al., 2011). When males are affected, they tend to have a later
onset and a poor prognosis. Other poor prognostic indicators
include, age greater than 50 years, rapid onset of symptoms
under 3 months, cigarette smoking, diabetes, severe or uncon-
trolled hyperthyroidism, pretibial myxedema, hyperlipidemia
and peripheral vascular disease (Stiebel-Kalish et al., 2009;
Yang et al., 2011; Stan and Bahn, 2010). It is believed that thy-
roid eye disease results from immunologic cross-reactivity be-
tween thyroid and orbital tissue antigens, thyroid stimulating
hormone receptor. Studies have shown that almost 50% of pa-
tients having Graves’ disease may have TAO and signiﬁcant of
them may develop visual complications as a result of compres-
sive optic neuropathy, diplopia or exposure keratopathy
(Yang et al., 2011; Douglas et al., 2011). Eyelid retraction
may be the presenting sign in the vast majority of patients hav-
ing TED. Some of the other presenting signs in TAO may in-
clude eyelid swelling, erythema and proptosis. A vast majority
of these patients present with an active inﬂammatory phase
which may last for one to two years. In TAO, mononuclear cell
inﬁltration consisting of helper/inducer CD4+ and suppres-
sor/cytotoxic CD8+ T lymphocytes, B lymphocytes, plasma
cells and macrophages may take place in the orbital fatty tis-
sue, extraocular muscles and lacrimal gland (Stiebel-Kalish
et al., 2009; Yang et al., 2011). Inﬂammatory process eventu-
ally may lead to the deposition of extracellular matrix material
including glycosaminoglycans such as hyaluronan causing an1319-4534 ª 2010 King Saud University. Production and hosting by
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fat resulting in restrictive strabismus and proptosis.
TAO may be diagnosed clinically by the presenting ocular
signs and symptoms, but positive tests for antibodies (anti-thy-
roglobulin, anti-microsomal and anti-thyrotropin receptor)
and abnormalities in thyroid hormones level (T3, T4 and
TSH) may be helpful in supporting the diagnosis. Computed
tomography scans may delineate between TED that results
predominately from fat expansion (type I) and TED that re-
sults predominately from extraocular muscle enlargement
(type II). Patients at high risk of compressive optic neuropathy
are those with enlarged extraocular muscles that may crowd
the orbital apex. Patients with TAO may need to be referred
to an internist or an endocrinologist for the evaluation and
management of systemic thyroid disease, as patients with
uncontrolled hyper- and hypothyroidism may be more likely
to have severe TAO than their counterpart euthyroid patients.
The strongest modiﬁable risk factor for disease progression is
cigarette smoking as the severity of the disease may be in-
creased in patients who are smokers.
The European Group on Graves’ Orbitopathy (EUGOGO)
(Bartalena et al., 2008) has stratiﬁed disease severity into three
categories to help guide treatment. According to the EUGO-
GO protocol, patients having sight-threatening TAO as a
result of compressive optic neuropathy or exposure keratopa-
thy may need immediate treatment in the form of systemic cor-
ticosteroids or surgery. However, long-term systemic
corticosteroids may result in substantial side effects by causing
hyperglycemia, hypertension, steroid-induced psychosis, sig-
niﬁcant weight gain by ﬂuid retention, decreased bone density,
gastric discomfort, insomnia and cushingoid features. Further,
intravenous corticosteroids may also cause hepatic toxicity,
including liver failure. Patients having moderate to severe
TAO may beneﬁt from immunosuppressive agents or orbital
radiotherapy. Immunosuppressants such as methotrexate, aza-
thioprine, and cyclosporine may be helpful alone in some pa-
tients or in combination with systemic corticosteroids in
other patients. Only up to 75% of the patients may respond
to standard immunosuppressive agents (Stiebel-Kalish et al.,
2009; Stan and Bahn, 2010). Experience has shown that intra-
venous corticosteroids may be more effective than oral cortico-
steroids in cases of moderate to severe active TAO. Local
2 Editorialcorticosteroids injection may be considered when oral or intra-
venous corticosteroids are contraindicated (Ebner et al., 2004).
Almost one-third of the patients with moderate to severe TAO
may not respond to systemic corticosteroids as expected. Local
orbital radiotherapy due to its anti-inﬂammatory effects and
alteration of helper/suppressor T lymphocyte ratio may be
considered in active TAO unless the patient has evidence of
diabetic retinopathy (Ebner et al., 2004). Risk of deﬁnite or
possible radiation retinopathy may be as high as 21% over a
10-year period (Bradley et al., 2008). Additional concern
regarding radiotherapy includes its carcinogenic potentials in
patients under 35-years of age and radiation-induced cataract
formation. Patients with mild TAO may beneﬁt from lubrica-
tion. Botulinum-induced transient upper eyelid ptosis may be
helpful in patients with exposure keratopathy due to eyelid
retraction and proptosis. Surgery is considered to be treatment
of choice for vision-threatening compressive optic neuropathy
or cosmetically disﬁguring inactive proptosis.
In this issue of Saudi Journal of Ophthalmology, Douglas
et al. (2011), discuss the potential pathogenesis and immuno-
logic mechanisms underlying Graves’ disease and TAO. They
point to the prominent role of orbital ﬁbroblasts, T cells and
B cells in the pathogenesis of TAO. Based on evidence from
the current research, Douglas et al. (2011), point to the role
of orbital ﬁbroblast as the target cell in TAO because of its im-
mune inﬁltration, cytokine production and antigen expression.
For example, orbital ﬁbroblast may exhibit pro-inﬂammatory
and pro-ﬁbrotic properties and may differentiate into either
myoﬁbroblast resulting in scar formation or lipoﬁbroblast
resulting in increased orbital adipose tissue. These ﬁbroblasts
may over-express CD40 receptor, the activation of which
may lead to expression of several cytokines and chemokines
which may result in the accumulation of glycosaminoglycans
in the orbit (Cao et al., 1998). The authors point to the fact
that advances in our current understanding of the pathophys-
iology of TAO have led to novel strategies for clinical treat-
ment of such patients by the use of immunomodulatory
agents such as inﬂiximab and etanercept (anti-TNF agents)
(Paridaens et al., 2005; Durrani et al., 2005). More recently,
there is an increasing interest in anti-B cell (Rituximab) ther-
apy because of its promising results in progressive, sight-
threatening TAO (Pescovitz et al., 2009; Khanna et al.,
2010). Rituximab is a mouse-human chimeric monoclonal
antibody targeting CD20 proteins or pre-B and mature B lym-
phocyte which blocks B-cell activation and differentiation but
does not affect B-cell regeneration from its stem cells or immu-
noglobulin production from B cells. These new immunomodu-
latory agents have been found to be particularly helpful in
patients unresponsive to systemic corticosteroids by their tar-
geting of the molecular mediators of the disease without the
potential side effects of non-speciﬁc therapies such as cortico-
steroids and radiotherapy.
In summary, TAO continues to be a challenge to manage
and one cannot disagree with Douglas et al. (2011), assertion
that ‘‘we are now in an exciting period due to considerable ad-
vances in our understanding of the role of speciﬁc immuno-
modulating agents that enable us to target the basis of the
disease rather than just addressing the symptoms and diseasemanifestations.’’ Currently, no single treatment, including cor-
ticosteroids, immunosuppressant agents, biologic agents or
radiation therapy provides any cure but palliation. It is hoped
that further studies may help in our understanding of the path-
ophysiology of TAO. Understanding of the mechanism of the
disease process as well as discovery of the target-speciﬁc agents
may offer optimal treatment for patients developing TAO.
More experience with novel agents may provide guidelines
for rational and standardized treatment of such patients.
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